ASCO: Combo Regimen Effective in CLL With Coexisting Conditions

TUESDAY, June 4, 2019 -- Venetoclax-obinutuzumab is associated with longer progression-free survival than chlorambucil-obinutuzumab among patients with untreated chronic lymphocytic leukemia (CLL) and coexisting conditions, according to a study...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news